<DOC>
	<DOCNO>NCT00841763</DOCNO>
	<brief_summary>The present study , phase III , randomize , control , observer-blind , multicenter study , evaluate safety , tolerability immunogenicity two dos adjuvanted monovalent influenza vaccine compare adjuvanted interpandemic trivalent influenza vaccine population healthy adult elderly subject .</brief_summary>
	<brief_title>Safety , Tolerability Immunogenicity Two Doses Adjuvanted Monovalent Influenza Vaccine Administered Healthy Adult Elderly Subjects</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects 18 year age old mentally competent sign informed consent form receive detailed explanation study protocol ; In good health determine : 1. medical history , 2. physical examination , 3. clinical judgment Investigator ; Able understand comply study procedure complete study diary , contact , available study visit ; Receipt another investigational agent within 4 week ; Laboratoryconfirmed influenza disease within 6 month prior Visit 1 ; Receipt influenza vaccination current season 2008/2009 ; Experienced acute disease infection require systemic antibiotic antiviral therapy ( chronic antibiotic therapy urinary tract prophylaxis acceptable ) within past 7 day ; Experienced fever ( defined axillary temperature 38.0°C ) within 7 day prior Visit 1 ; Pregnant breastfeeding ; Females childbearing potential sexually active use plan refuse use acceptable method birth control active phase study ( least three week last vaccine injection ) ; Any serious disease , : cancer , autoimmune disease ( include rheumatoid arthritis ) ; diabetes mellitus type I type II ; diabetes relate genetic defects/syndromes , disease exocrine pancreas infection ; advance arteriosclerotic disease ; severe chronic obstructive pulmonary disease ( COPD ) , i.e . GOLD stag 3 4 ; acute progressive hepatic disease renal disease ; congestive heart failure ; Body Mass Index ≥35 kg/m2 BMI reflect obesity high muscle mass ; History progressive severe neurologic disorder , neurological symptom sign , anaphylactic shock follow administration study vaccine ; Surgery plan study period ; Hypersensitivity egg , chicken protein , chicken feather , influenza viral protein , neomycin polymyxin component study vaccine ; Known suspect impairment/alteration immune function , example , result : 1. receipt immunosuppressive therapy ( corticosteroid therapy cancer chemotherapy ) immunosuppressive agent within past 60 day full length study ; 2. receipt immunostimulants ; 3. receipt parenteral immunoglobulin preparation , blood product and/or plasma derivates within past 3 month full length study ; 4. suspect know HIV infection HIVrelated disease ; Receipt non study vaccine ( exception postexposure vaccination medical emergency , e.g . hepatitis , rabies , tetanus ) within 3 week prior Visit 1 plan vaccination within 3 week follow last study vaccination ; History ( current ) drug alcohol abuse investigator 's opinion would interfere safety subject evaluation study objective ; Members research staff relatives ; Any condition , , opinion Investigator , might interfere evaluation study objective .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>virus</keyword>
	<keyword>pandemic influenza</keyword>
	<keyword>vaccine</keyword>
</DOC>